Discovery of Small-Molecule Inhibitors of the TLR1/TLR2 Complex

Authors

  • Dr. Kui Cheng,

    1. Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)
    Search for more papers by this author
  • Dr. Xiaohui Wang,

    1. Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)
    Search for more papers by this author
  • Shuting Zhang,

    1. Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)
    Search for more papers by this author
  • Prof. Dr. Hang Yin

    Corresponding author
    1. Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)
    • Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309 (USA)
    Search for more papers by this author

  • We thank the U.S. National Institutes of Health (DA026950, DA025740s and NS067425) for financial support of this work. The sTLR2 DNA plasmid was kindly provided by Dr. Chiaki Nishitani and Dr. Yoshio Kuroki.

Abstract

original image

An important regulator of innate immunity, the protein complex of Toll-like receptors 1 and 2 (TLR1/TLR2) provides an attractive target for the treatment of various immune disorders. The novel compound CU-CPT22 can compete with the binding of the specific lipoprotein ligand to TLR1/TLR2 (see picture) with high inhibitory activity and specificity. Repression of downstream signaling from TNF-α and IL-1β was also observed.

Ancillary